A Multicenter, Dose-Optimized, Open-Label Safety Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Phase of Trial: Phase III
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs Serdexmethylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
- Sponsors KemPharm
- 16 Aug 2019 Status changed from recruiting to completed.
- 19 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.
- 19 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Jun 2019.